Navigation Links
Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
Date:11/5/2007

tudy, more than 3,000 patients were tested for Haptoglobin phenotype, and 984 of these who had the Hp2-2 phenotype were randomized to receive either natural source Vitamin E (400 IU daily) or placebo. Primary endpoints of the study were non-fatal myocardial infarction (MI--heart attack), stroke and cardiovascular death. Results demonstrated a greater than 50% decrease in cardiovascular events in patients receiving Vitamin E (1.0 percent compared to 3.8 percent, p=0.004), leading to early termination of the study. Investigators determined this result to be predominantly due to a significant decrease in non-fatal myocardial infarction in the Vitamin E group.

"Our research group has postulated that the profoundly increased risk of, MI, stroke and cardiovascular death observed in DM patients with Hp2-2, established in many observational studies of more than 20,000 patients in recent years, may be a consequence of a defect in the antioxidant protection of Hp2-2," added Dr. Levy. "As a member of my group, Dr. Rabea Asleh, reported earlier today, this defect may interfere with reverse cholesterol transport. This in turn may promote a more inflamed and labile atherosclerotic plaque. It is gratifying to have had this opportunity to collaborate with Clalit Health Services, the largest health plan in Israel, in a large prospective clinical trial that provides strong support for the claim that Vitamin E can be targeted to DM patients with Hp2-2 and provide a significant clinical benefit."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metaboliz
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Today, the ... (NABP ® ) issued a report urging greater ... action is taken against websites illegally selling medications ... Drug Outlet Identification Program Progress Report for State ... thousands of websites illegally distribute medications and ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
(Date:7/31/2015)... , July 31, 2015 The Physician-Patient ... release on July 28, 2015, "Surviving Your Hospital ... Fundraising for Patient Safety." A sentence ... should read: "PPAHS is a member ... on Opioids. For more information on the National Coalition ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... SPRING, Md., May 13, 2011  The following was ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Fast Facts ... use products marketed as dietary supplements that also claim ... illegal products are falsely promoted with claims to treat ...
... 13, 2011 Amgen (NASDAQ: AMGN ) will ... (AUA) Conference on Tuesday, May 17 at 12:00 p.m. Eastern ... clinical investigator will participate at the meeting to discuss data ... the conference call will be simultaneously broadcast over the Internet ...
Cached Medicine Technology:FDA: Don't Buy Drugs Marketed as Antimicrobial Dietary Supplements 2FDA: Don't Buy Drugs Marketed as Antimicrobial Dietary Supplements 3FDA: Don't Buy Drugs Marketed as Antimicrobial Dietary Supplements 4Amgen to Webcast Investor Meeting at Upcoming American Urological Association Conference 2
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... a one-day event geared to patients and family members, medical professionals, and researchers, ... regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma Applied ...
(Date:7/31/2015)... ... July 31, 2015 , ... Transfinder, a software company based in ... were up 16 percent year-over-year for the first six months ended June 30, 2015 ... expected Transfinder to beat last year’s record-revenue mark of $10.4 million. , “We know ...
(Date:7/31/2015)... ... ... Creating one of the most modern fertility centers in the Middle East, ... beyond the boundaries of fertility medicine. , As the leading gynecology and fertility ... support, affordable treatments, unending hope, and high fertility success rates — all contributing to ...
(Date:7/31/2015)... MA (PRWEB) , ... July 31, 2015 , ... ... this year’s “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, ... November 5 and 6. The event attracts over 250 “C”-level executives, administrators, ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Girl ... stamp out bullying across Georgia through the Girl Scout "Be a Friend First" program. ... on Thursday, July 30. , “Peach State Health Plan and our parent company, ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... Sales and Pro Forma EPS Guidance, BETHESDA, Md., July ... net sales of $181.2 million for the,quarter ended June 30, ... year,s comparable quarter. Net income increased by $2.9 million, or,57.2%, ... million in same,quarter last year., Pro forma net income ...
... International and,Elanco today announced that they have signed ... hunger organization. Elanco is,an animal health company headquartered ... around the world. Elanco makes veterinary medicines,and products ... partnership will engage the unique talents of Elanco,s ...
... suggests brain needs ,experience replay, during slumber , , TUESDAY, ... of memories during sleep, a process that,s crucial for ... University of Arizona researchers. , The researchers recorded ... in learning and memory -- in 11 young and ...
... announced today that Craig M. Walker, M.D., has been ... of directors from,four to five. Dr. Walker brings over ... investigator and thought leader., "Dr. Walker will be ... the,world,s leading experts in the care of patients with ...
... H.R. 1108 Allows FDA Un-Precedential Regulatory Authority Over ... largest,Hispanic faith-based organization in the country, presses Congress ... and pass H.R 1108, "The,Family Smoking Prevention and ... ability to regulate tobacco products and marketing in ...
... Calif., July 29 Align,Technology, Inc. (Nasdaq: ... its,Invisalign product family: Invisalign Teen for non-adult, comprehensive,orthodontic ... that meet their desire for aesthetic treatment and ... of sports, music and,other activities. According to consumer ...
Cached Medicine News:Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 2Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 3Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 4Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 5Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 6Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 7Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 8Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 9Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 10Health News:Heifer and Elanco Announce Charitable Partnership 2Health News:Aging Hinders Memory Storage During Sleep 2Health News:VASAMED(R) Appoints Craig M. Walker, MD to Board of Directors 2Health News:Align Technology Targets Mainstream Orthodontics Market With Invisalign Teen(TM) 2Health News:Align Technology Targets Mainstream Orthodontics Market With Invisalign Teen(TM) 3Health News:Align Technology Targets Mainstream Orthodontics Market With Invisalign Teen(TM) 4
Slightly curved 10 mm jaws and serrated cross action handle with polished finish. Overall length 4.6 inches....
Hartman Mosquito forceps, straight, 3.5"....
Curved 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 3.9 inches...
Shafts angled 45 degrees with 10 mm jaws. Serrated handle with polished finish. Crisscross serrated jaws. Most popular size or model....
Medicine Products: